Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737024 | 1.00 | MAPT (0.38) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL3269278 | 1.00 | MAPT (0.38) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL7737027 | 1.00 | MAPT (0.38) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL7737022 | 1.00 | MAPT (0.38) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL20969242 | 0.96 | MAPT (0.36) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL3270112 | 0.90 | CYP2C9 (0.42) | MAPTMEN1KMT2AOPRL1CYP2C9 | |
| SCHEMBL1574998 | 0.90 | CYP2C9 (0.42) | MAPTMEN1KMT2AOPRL1CYP2C9 | |
| SCHEMBL13293543 | 0.90 | CYP2C9 (0.42) | MAPTMEN1KMT2AOPRL1CYP2C9 | |
| SCHEMBL12733579 | 0.87 | MAPT (0.38) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL18559471 | 0.87 | MAPT (0.42) | MAPTGAAMEN1KMT2AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4349842-B1 | HYDROXYAMINOPHOSPHINIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260132157-A1 | HYDROXYAMINOPHOSPHINIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-05-14 | — | — | US | disclosed |
| US-12424277-B2 | Electronic switching device | MERCK PATENT GMBH (DE) | 2025-09-23 | — | — | US | disclosed |
| EP-4062453-B1 | ELECTRONIC SWITCHING DEVICE | MERCK PATENT GMBH (DE) | 2025-06-04 | — | — | EP | disclosed |
| CN-119998303-A | Hydroxy amino phosphinic acid derivatives | 默克专利有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4494430-A1 | ELECTRONIC SWITCHING DEVICE | Merck Patent GmbH (DE) | 2025-01-22 | — | — | EP | disclosed |
| US-20250011349-A1 | ELECTRONIC SWITCHING DEVICE | MERCK PATENT GMBH (DE) | 2025-01-09 | — | — | US | disclosed |
| US-12193328-B2 | Aromatic compounds and use thereof for formation of molecular layers and fabrication of switching elements for memristive devices | MERCK PATENT GMBH (DE) | 2025-01-07 | — | — | US | disclosed |
| CN-113812003-B | Aromatic compounds | 默克专利有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-118923223-A | Electronic switching device | 默克专利有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-2305627-B1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-20140138581-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-8580142-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8580142-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20100328600-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100328600-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2199270-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-7166337-B2 | Liquid-crystal composition, methods of adjusting the resistance, and substituted phenols | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | MAPT 1075/4885GAA 4763/4885MEN1 2496/4885 |
| US-20260132157-A1 | HYDROXYAMINOPHOSPHINIC ACID DERIVATIVES | OR10J3, OXSR1, OXER1 | MAPT 3283/4885GAA 4715/4885MEN1 2409/4885 |
| US-12193328-B2 | Aromatic compounds and use thereof for formation of molecular layers and fabrication of switching elements for memristive devices | CHRM1, CCNB1, CCNL2 | MAPT 2663/4885GAA 2685/4885MEN1 115/4885 |
| US-12424277-B2 | Electronic switching device | L1CAM, GRIN2B, NBAS | MAPT 1283/4885GAA 4554/4885MEN1 1078/4885 |
| US-20100328600-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, MARK3, CCND3 | MAPT 271/4885GAA 4848/4885MEN1 3906/4885 |
| US-20250011349-A1 | ELECTRONIC SWITCHING DEVICE | L1CAM, OR10J3, GJA1 | MAPT 1271/4885GAA 4561/4885MEN1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.